Additional effects of herbal medicine combined with bisphosphonates for primary osteoporosis: a systematic review and meta-analysis

IF 4.4 2区 医学 Q1 PHARMACOLOGY & PHARMACY Frontiers in Pharmacology Pub Date : 2024-09-13 DOI:10.3389/fphar.2024.1413515
Young-Seo Yoo, Min-Gyeong Kim, Hee-Joo Park, Min-Young Chae, Yu-Jin Choi, Chae-Kun Oh, Chang-Gue Son, Eun-Jung Lee
{"title":"Additional effects of herbal medicine combined with bisphosphonates for primary osteoporosis: a systematic review and meta-analysis","authors":"Young-Seo Yoo, Min-Gyeong Kim, Hee-Joo Park, Min-Young Chae, Yu-Jin Choi, Chae-Kun Oh, Chang-Gue Son, Eun-Jung Lee","doi":"10.3389/fphar.2024.1413515","DOIUrl":null,"url":null,"abstract":"BackgroundOsteoporosis (OP) is a significant medical issue associated with population aging. Recent research on herbal medicines (HMs) for OP has been increasing, with these therapies sometimes used in conjunction with bisphosphonates (BPs), the standard treatment for OP. We conducted a systematic review and meta-analysis to evaluate the effects of combining HMs with BPs on improving bone mineral density (BMD) in patients with primary OP.MethodsWe searched nine databases—PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure Wanfang, KISS, Kmbase, Science On, and Oasis—up to 31 August 2023. We selected randomized controlled trials (RCTs) comparing BMD between HMs <jats:italic>plus</jats:italic> BPs and BPs alone in primary OP. A meta-analysis with BMD as the primary outcome was performed using RevMan version 5.4. Study quality and evidence certainty were assessed through Cochrane’s risk of bias2 and GRADE.ResultsOut of 43 RCTs involving 4,470 participants (mean age 65.8 ± 6.6 years), 35 RCTs with 3,693 participants were included in the meta-analysis. The combination of HMs and BPs was found to be more effective in improving BMD compared to BPs alone, with improvements of 0.10 g/cm<jats:sup>2</jats:sup> at the lumbar spine (33 RCTs, 95% CI: 0.07–0.12, <jats:italic>p</jats:italic> &amp;lt; 0.001, I<jats:sup>2</jats:sup> = 93%) and 0.08 g/cm<jats:sup>2</jats:sup> at the femoral neck (20 RCTs, 95% CI: 0.05–0.12, <jats:italic>p</jats:italic> &amp;lt; 0.001, I<jats:sup>2</jats:sup> = 94%), though this result was associated with high heterogeneity, high risk of bias, and very low certainty of evidence.ConclusionOur data suggest the possibility that combining HMs with BPs may improve BMD in primary OP more effectively than using BPs alone. However, the results should be interpreted with caution due to the high heterogeneity and low quality of the studies included in the review. Therefore, further well-designed RCTs are needed to confirm these findings.Systematic Review Registration<jats:ext-link>https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023392139</jats:ext-link>.","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.4000,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphar.2024.1413515","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

BackgroundOsteoporosis (OP) is a significant medical issue associated with population aging. Recent research on herbal medicines (HMs) for OP has been increasing, with these therapies sometimes used in conjunction with bisphosphonates (BPs), the standard treatment for OP. We conducted a systematic review and meta-analysis to evaluate the effects of combining HMs with BPs on improving bone mineral density (BMD) in patients with primary OP.MethodsWe searched nine databases—PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure Wanfang, KISS, Kmbase, Science On, and Oasis—up to 31 August 2023. We selected randomized controlled trials (RCTs) comparing BMD between HMs plus BPs and BPs alone in primary OP. A meta-analysis with BMD as the primary outcome was performed using RevMan version 5.4. Study quality and evidence certainty were assessed through Cochrane’s risk of bias2 and GRADE.ResultsOut of 43 RCTs involving 4,470 participants (mean age 65.8 ± 6.6 years), 35 RCTs with 3,693 participants were included in the meta-analysis. The combination of HMs and BPs was found to be more effective in improving BMD compared to BPs alone, with improvements of 0.10 g/cm2 at the lumbar spine (33 RCTs, 95% CI: 0.07–0.12, p &lt; 0.001, I2 = 93%) and 0.08 g/cm2 at the femoral neck (20 RCTs, 95% CI: 0.05–0.12, p &lt; 0.001, I2 = 94%), though this result was associated with high heterogeneity, high risk of bias, and very low certainty of evidence.ConclusionOur data suggest the possibility that combining HMs with BPs may improve BMD in primary OP more effectively than using BPs alone. However, the results should be interpreted with caution due to the high heterogeneity and low quality of the studies included in the review. Therefore, further well-designed RCTs are needed to confirm these findings.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023392139.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
中药联合双磷酸盐治疗原发性骨质疏松症的额外效果:系统综述和荟萃分析
背景骨质疏松症(OP)是与人口老龄化相关的一个重要医疗问题。近年来,有关中草药(HMs)治疗骨质疏松症的研究日益增多,这些疗法有时与双磷酸盐(BPs)结合使用,而双磷酸盐是治疗骨质疏松症的标准疗法。我们进行了一项系统综述和荟萃分析,以评估将 HMs 与 BPs 结合使用对改善原发性 OP 患者骨矿密度(BMD)的效果。我们选择了一些随机对照试验 (RCT),这些试验比较了 HMs 加 BPs 和单纯 BPs 在初级 OP 中的 BMD。使用 RevMan 5.4 版进行了以 BMD 为主要结果的荟萃分析。通过 Cochrane 的偏倚风险2 和 GRADE 对研究质量和证据确定性进行了评估。结果在 43 项涉及 4470 名参与者(平均年龄为 65.8 ± 6.6 岁)的 RCT 中,有 35 项涉及 3693 名参与者的 RCT 纳入了荟萃分析。研究发现,与单独使用 BPs 相比,HMs 和 BPs 的组合能更有效地改善 BMD,腰椎的改善幅度为 0.10 g/cm2(33 项 RCT,95% CI:0.07-0.12,p &;lt;0.001,I2 = 93%),股骨颈的改善幅度为 0.08 g/cm2(20 项 RCT,95% CI:0.05-0.12,p &;lt;0.001,I2 = 93%)。结论我们的数据表明,在原发性 OP 中,将 HMs 与 BPs 结合使用可能比单独使用 BPs 更有效地改善 BMD。然而,由于本综述所纳入研究的异质性较高且质量较低,因此在解释结果时应谨慎。因此,需要进一步设计良好的 RCT 来证实这些结果。系统综述注册https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023392139。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Frontiers in Pharmacology
Frontiers in Pharmacology PHARMACOLOGY & PHARMACY-
CiteScore
7.80
自引率
8.90%
发文量
5163
审稿时长
14 weeks
期刊介绍: Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
期刊最新文献
The glucocorticoid dose-mortality nexus in pneumonia patients: unveiling the threshold effect. The impact of EU public procurement regulations on tenders in Spain: a study with adalimumab. The role of TRPV1 in chronic prostatitis: a review. Transcriptomics-based anti-tuberculous mechanism of traditional Chinese polyherbal preparation NiuBeiXiaoHe intermediates. Applications and challenges of photodynamic therapy in the treatment of skin malignancies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1